We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BURL:NYSEBurlington Stores, Inc. Analysis

Data as of 2026-03-11 - not real-time

$305.47

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Burlington Stores (BURL) has just delivered a strong fourth‑quarter performance, with sales climbing double‑digits year‑over‑year and adjusted earnings beating consensus, prompting analysts to lift price targets and the stock to rally sharply. The technical backdrop remains bullish – the price sits above both the 20‑day and 50‑day moving averages and comfortably above the 200‑day average, while volume is on an upward trend, supporting the upside momentum. However, the MACD shows a bearish histogram and the RSI hovers around the neutral 50 mark, suggesting that short‑term momentum may be softening as the price approaches the upper end of its recent range.
Fundamentally, the company commands a PE in the low‑30s (forward PE in the low‑20s) and a price‑to‑book near 11×, which places valuation on the higher side for the off‑price retail segment. Strong profitability metrics – ROE approaching 40% and operating margins above 11% – are offset by a very high debt‑to‑equity ratio exceeding 300, indicating leverage risk. The blend of robust earnings growth, elevated valuation multiples, and moderate technical over‑extension frames a nuanced investment case.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Recent earnings beat and raised price targets
  • Price near short‑term resistance with bearish MACD histogram
  • Increasing volume supporting current trend

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained revenue growth and strong ROE
  • Upside potential of roughly 20% to analyst median target
  • Bullish trend above key moving averages

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High leverage (debt‑to‑equity >300) poses balance‑sheet risk
  • Valuation multiples remain elevated relative to peers
  • Long‑term brand positioning in the off‑price segment

Key Metrics & Analysis

Financial Health

Revenue Growth11.30%
Profit Margin5.28%
P/E Ratio32.2
ROE38.40%
ROA5.73%
Debt/Equity332.28
P/B Ratio10.8
Op. Cash Flow$1.2B
Free Cash Flow$109.5M

Technical Analysis

TrendBullish
RSI50.3
Support$288.16
Resistance$332.20
MA 20$307.03
MA 50$303.29
MA 200$274.31
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91

Valuation

Target Price$370.50
Upside/Downside21.29%
GradeOvervalued
TypeBlend

Risk Assessment

Beta1.13
Volatility36.81%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.